Download full-text PDF

Source

Publication Analysis

Top Keywords

[hepatic cirrhosis
4
cirrhosis aged
4
aged morphologic
4
morphologic biohumeral
4
biohumeral clinical
4
clinical aspects
4
aspects cases
4
cases therapeutic
4
therapeutic prospectives]
4
[hepatic
1

Similar Publications

Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.

J Gastroenterol

January 2025

Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.

Background: Advanced liver fibrosis in cases of metabolic dysfunction-associated steatotic liver disease (MASLD) leads to cirrhosis and hepatocellular carcinoma. The current gold standard for liver fibrosis is invasive liver biopsy. Therefore, a less invasive biomarker that accurately reflects the stage of liver fibrosis is highly desirable.

View Article and Find Full Text PDF

Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System.

Trends Cardiovasc Med

January 2025

Department of Cardiology, Euroclinic Hospital, Athens, Greece; First Department of Cardiology, Athens University School of Medicine, Athens, Greece. Electronic address:

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty-liver disease, is an important and rising health issue with a link with atherosclerotic cardiovascular (CV) disease (CVD), affecting ∼25-30% of the adults in the general population; in patients with diabetes, its prevalence culminates to ∼70%; its evolutive form, nonalcoholic steatohepatitis, is estimated to be the main cause of liver transplantation in the future. MASLD is a multisystem disease that affects, besides the liver, extra-hepatic organs and regulatory pathways; it raises the risk of type 2 diabetes mellitus (T2D), CVD, and chronic kidney disease; the disease may also progress to hepatocellular carcinoma. Its diagnosis requires hepatic steatosis and at least one cardiometabolic risk factor and the exclusion of both significant alcohol consumption and other competing causes of chronic liver disease.

View Article and Find Full Text PDF

Percutaneous Magnetic Resonance Imaging-Guided Microwave Ablation for Patients with Cirrhosis Complicated by Small Hepatocellular Carcinoma.

J Vasc Interv Radiol

January 2025

Department of Interventional Radiology, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China; Department of Interventional Radiology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China; Fujian Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China.

Objective: To assess the technical effectiveness and therapeutic outcomes of percutaneous magnetic resonance (MR)-guided microwave ablation (MWA) in the treatment of patients with cirrhosis complicated by small hepatocellular carcinoma (HCC).

Materials And Methods: A single center retrospective analysis of consecutive cases involving 1.5T MR-guided MWA for hepatocellular carcinoma was performed.

View Article and Find Full Text PDF

Background Aims: Hepatitis B virus (HBV) leads to severe liver diseases, such as cirrhosis and hepatocellular carcinoma. Identification of host factors that regulate HBV replication can provide new therapeutic targets. The discovery of sodium taurocholate cotransporting polypeptide (NTCP) as an HBV entry receptor has enabled the establishment of hepatic cell lines for analyzing HBV infection and propagation.

View Article and Find Full Text PDF

Background: Chronic infection with hepatitis B virus and HIV causes significant morbidity and mortality. Effective antiviral treatment is available for both. Ireland has historically been considered a low prevalence country.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!